Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis
Launched by CXLUSA · Nov 30, 2012
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subjects must be 18 years of age or older.
- • 2. Ability to provide written informed consent.
- • 3. Likely to complete all study visits.
- • 4. Subjects must have one eye that with a diagnosis of infectious keratitis.
- Exclusion Criteria:
- • 1. A corneal perforation.
- • 2. Descemetocele.
- • 3. Pregnancy or breastfeeding.
- • 4. Active Herpes corneal disease.
- • 5. Patient is unwilling or unable to comply with a medication regimen and follow up appointments.
About Cxlusa
CXLUSA is a leading clinical trial sponsor dedicated to advancing corneal health through innovative research and development. Focused on providing cutting-edge therapies for conditions such as keratoconus and other corneal diseases, CXLUSA collaborates with esteemed research institutions and healthcare professionals to conduct rigorous clinical trials. Committed to enhancing patient outcomes, the organization emphasizes the importance of scientific integrity and regulatory compliance in its operations, ensuring that all trials adhere to the highest ethical standards. Through its pioneering efforts, CXLUSA aims to transform the landscape of ophthalmic care and improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
West Hills, California, United States
Saint Louis, Missouri, United States
Minneapolis, Minnesota, United States
Scottsdale, Arizona, United States
Littleton, Colorado, United States
Miami, Florida, United States
Patients applied
Trial Officials
William Trattler, MD
Study Director
Center For Excellence In Eye Care
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials